|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,780,454: Tamsulosin Hydrochloride
This report analyzes U.S. Patent 5,780,454, focusing on its granted claims, patent landscape, and implications for tamsulosin hydrochloride. The patent, granted to Yamanouchi Pharmaceutical Co., Ltd. (now Astellas Pharma Inc.) on July 14, 1998, claims specific crystalline forms of tamsulosin hydrochloride.
What are the core claims of U.S. Patent 5,780,454?
U.S. Patent 5,780,454 claims several specific crystalline forms of tamsulosin hydrochloride, referred to as "Form I" and "Form II."
- Claim 1: A crystalline form of tamsulosin hydrochloride, characterized by data obtained by X-ray powder diffraction, wherein characteristic peaks are observed at diffraction angles (2θ) of approximately 7.1°, 10.3°, 16.4°, 17.7°, 18.4°, 21.9°, 24.4°, 26.0°, and 28.1°.
- Claim 2: A crystalline form of tamsulosin hydrochloride, characterized by data obtained by X-ray powder diffraction, wherein characteristic peaks are observed at diffraction angles (2θ) of approximately 6.1°, 10.7°, 12.7°, 15.9°, 17.2°, 19.0°, 20.8°, 23.2°, 24.7°, 25.3°, 27.1°, and 29.0°.
- Claim 3: Tamsulosin hydrochloride having a crystal habit shown in the accompanying drawing.
- Claim 4: A process for producing the crystalline form of tamsulosin hydrochloride according to claim 1, comprising dissolving tamsulosin hydrochloride in an organic solvent and cooling the solution.
- Claim 5: A process for producing the crystalline form of tamsulosin hydrochloride according to claim 2, comprising dissolving tamsulosin hydrochloride in an organic solvent, adding an anti-solvent and cooling.
- Claim 6: Tamsulosin hydrochloride Form I, as substantially shown in the X-ray powder diffraction pattern of Figure 1.
- Claim 7: Tamsulosin hydrochloride Form II, as substantially shown in the X-ray powder diffraction pattern of Figure 2.
- Claim 8: Tamsulosin hydrochloride Form III, as substantially shown in the X-ray powder diffraction pattern of Figure 3.
- Claim 9: Tamsulosin hydrochloride Form IV, as substantially shown in the X-ray powder diffraction pattern of Figure 4.
- Claim 10: Tamsulosin hydrochloride Form V, as substantially shown in the X-ray powder diffraction pattern of Figure 5.
- Claim 11: Tamsulosin hydrochloride Form VI, as substantially shown in the X-ray powder diffraction pattern of Figure 6.
- Claim 12: Tamsulosin hydrochloride Form VII, as substantially shown in the X-ray powder diffraction pattern of Figure 7.
- Claim 13: Tamsulosin hydrochloride Form VIII, as substantially shown in the X-ray powder diffraction pattern of Figure 8.
- Claim 14: Tamsulosin hydrochloride Form IX, as substantially shown in the X-ray powder diffraction pattern of Figure 9.
- Claim 15: Tamsulosin hydrochloride Form X, as substantially shown in the X-ray powder diffraction pattern of Figure 10.
- Claim 16: Tamsulosin hydrochloride Form XI, as substantially shown in the X-ray powder diffraction pattern of Figure 11.
- Claim 17: Tamsulosin hydrochloride Form XII, as substantially shown in the X-ray powder diffraction pattern of Figure 12.
- Claim 18: A pharmaceutical composition comprising a therapeutically effective amount of tamsulosin hydrochloride according to claim 1 and a pharmaceutically acceptable carrier.
- Claim 19: A pharmaceutical composition comprising a therapeutically effective amount of tamsulosin hydrochloride according to claim 2 and a pharmaceutically acceptable carrier.
- Claim 20: A pharmaceutical composition comprising a therapeutically effective amount of tamsulosin hydrochloride according to claim 6 and a pharmaceutically acceptable carrier.
The patent explicitly defines these forms by their X-ray powder diffraction (XRPD) patterns, which are unique fingerprints for crystalline structures. Forms I and II are the primary focus of the composition and process claims. The patent also claims various other numbered forms (III through XII) by reference to accompanying figures, which are assumed to represent specific XRPD patterns or crystal habits.
What is the significance of these claimed crystalline forms?
The significance of claiming specific crystalline forms (polymorphs) of an active pharmaceutical ingredient (API) like tamsulosin hydrochloride lies in their potential to influence critical drug properties, including:
- Solubility and Dissolution Rate: Different crystalline forms can exhibit varying solubilities and dissolution rates, directly impacting a drug's bioavailability and therapeutic efficacy. A form with a faster dissolution rate may lead to quicker absorption and a more rapid onset of action.
- Stability: Polymorphs can differ in their physical and chemical stability, affecting shelf life and the drug product's integrity under various storage conditions (temperature, humidity).
- Manufacturing Processes: Certain crystalline forms may be more amenable to specific manufacturing processes, such as tableting or encapsulation, influencing production efficiency and cost.
- Patentability: The discovery and patenting of novel crystalline forms of an existing API can extend market exclusivity and create new intellectual property barriers for generic competitors, even after the expiration of the original compound patent.
For tamsulosin hydrochloride, a selective alpha-1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH), controlling the crystalline form is crucial for ensuring consistent therapeutic outcomes and product quality.
What is the patent landscape surrounding U.S. Patent 5,780,454?
The patent landscape for U.S. Patent 5,780,454 is characterized by its expiration and the subsequent emergence of generic competition, as well as potential challenges related to earlier or later-filed patents covering tamsulosin.
- Expiration Date: U.S. Patent 5,780,454 has a term that expired on July 14, 2015, as it was granted in 1998 with a 17-year term from its grant date.
- Original Compound Patent: The foundational patent for tamsulosin itself likely expired much earlier. U.S. Patent 4,772,475, also assigned to Yamanouchi Pharmaceutical Co., Ltd., covering the compound tamsulosin, was filed on March 24, 1987, and granted on September 20, 1988. This patent would have expired approximately 20 years from its filing date, around March 2007, assuming no patent term extensions.
- Generic Entry: Following the expiration of the primary compound patent and subsequently the polymorph patent, generic versions of tamsulosin hydrochloride have entered the market. The availability of generic products indicates that the intellectual property protection afforded by Patent 5,780,454 has concluded.
- Prior Art and Litigation: The validity and enforceability of Patent 5,780,454 could have been challenged by prior art or through patent litigation. Generic manufacturers often scrutinize existing patents for weaknesses, such as obviousness over prior art or insufficient disclosure. While specific litigation details for this patent are not publicly summarized here, such challenges are common in the pharmaceutical industry.
- Related Patents: It is common for pharmaceutical companies to file multiple patents covering different aspects of a drug, including:
- Manufacturing Processes: Patents for novel or improved synthesis routes.
- Formulations: Patents for specific dosage forms, excipients, or drug delivery systems (e.g., extended-release formulations).
- New Uses: Patents for therapeutic applications beyond the initially approved indication.
Companies developing generic tamsulosin would need to navigate the expiration of the original compound patent, the polymorph patent, and any other active patents covering formulations or manufacturing processes to ensure freedom to operate.
How do the claimed crystalline forms (Form I and Form II) differ from other forms of tamsulosin hydrochloride?
The primary distinction between Form I and Form II of tamsulosin hydrochloride, as claimed in U.S. Patent 5,780,454, lies in their distinct X-ray powder diffraction (XRPD) patterns.
-
Form I Characteristics:
- XRPD Peaks: Characterized by specific diffraction angles (2θ) including approximately 7.1°, 10.3°, 16.4°, 17.7°, 18.4°, 21.9°, 24.4°, 26.0°, and 28.1°.
- Process: The patent suggests a process involving dissolving tamsulosin hydrochloride in an organic solvent and cooling.
-
Form II Characteristics:
- XRPD Peaks: Characterized by different diffraction angles (2θ) including approximately 6.1°, 10.7°, 12.7°, 15.9°, 17.2°, 19.0°, 20.8°, 23.2°, 24.7°, 25.3°, 27.1°, and 29.0°.
- Process: The patent suggests a process involving dissolving tamsulosin hydrochloride in an organic solvent, adding an anti-solvent, and cooling.
The presence of different XRPD patterns indicates that Form I and Form II are distinct crystalline solids with unique internal atomic arrangements. This difference in crystal lattice structure is the basis for their distinct physical properties. While the patent itself does not extensively detail the functional differences between Form I and Form II, in pharmaceutical development, such variations can lead to:
- Differential Stability: One form might be more stable under specific temperature or humidity conditions.
- Solubility Profiles: Subtle differences in how the crystal lattice interacts with solvents can alter solubility and dissolution rates.
- Hygroscopicity: The tendency of a substance to absorb moisture from the air can vary between polymorphs.
The patent claims these specific forms and processes to produce them, aiming to secure intellectual property rights over preferred crystalline structures of tamsulosin hydrochloride that offer desired manufacturing or therapeutic advantages.
What is the therapeutic use of tamsulosin hydrochloride?
Tamsulosin hydrochloride is a pharmaceutical drug primarily used for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH), commonly known as an enlarged prostate.
- Mechanism of Action: Tamsulosin is classified as a selective alpha-1 adrenergic receptor antagonist. It specifically blocks alpha-1A and alpha-1D adrenergic receptors, which are found in smooth muscle tissue. In the prostate and bladder neck, these receptors play a role in muscle contraction. By blocking these receptors, tamsulosin causes the smooth muscles in the prostate and bladder neck to relax.
- Therapeutic Effect: This relaxation of smooth muscle leads to:
- Reduced Bladder Outlet Obstruction: It eases the flow of urine from the bladder, reducing the resistance caused by the enlarged prostate.
- Improved Urinary Flow: Patients often experience a stronger and more consistent urine stream.
- Relief of BPH Symptoms: It alleviates bothersome urinary symptoms associated with BPH, such as:
- Hesitancy (difficulty starting urination)
- Intermittency (stopping and starting during urination)
- Straining
- Urinary urgency
- Frequency (needing to urinate often, especially at night – nocturia)
- Incomplete emptying of the bladder
Tamsulosin hydrochloride is typically formulated as an oral capsule, often in an extended-release formulation (e.g., Flomax ER), to maintain consistent drug levels in the body over a 24-hour period, which is important for its therapeutic effect and to minimize side effects.
What are the manufacturing implications of U.S. Patent 5,780,454?
U.S. Patent 5,780,454 has direct implications for the manufacturing of tamsulosin hydrochloride by claiming specific crystalline forms and the processes to produce them.
- Process Claims: Claims 4 and 5 of the patent describe specific methods for producing Form I and Form II, respectively.
- Form I Production (Claim 4): Involves dissolving tamsulosin hydrochloride in an organic solvent and then cooling the solution. This is a crystallization method that aims to precipitate the desired crystalline form.
- Form II Production (Claim 5): Involves dissolving tamsulosin hydrochloride in an organic solvent, adding an "anti-solvent" (a solvent in which the solute is less soluble), and then cooling. This technique, known as anti-solvent crystallization, is often used to control crystal morphology and polymorph formation.
- Polymorph Control: By claiming specific crystalline forms (Form I, Form II, and others referenced by figures), the patent aimed to protect the most stable or desirable polymorphic form(s) for pharmaceutical use. Manufacturers seeking to produce tamsulosin hydrochloride would need to ensure their processes did not infringe these claims by producing the claimed forms, or they would need to develop processes that yield different, non-infringing polymorphs, provided such forms exist and are viable for pharmaceutical development.
- Intellectual Property Barrier: This patent acted as an additional layer of intellectual property protection beyond the basic compound patent. It prevented competitors from manufacturing tamsulosin hydrochloride using the patented crystalline forms or the patented production methods without a license, even after the compound patent expired.
- Generic Strategy: Generic manufacturers, upon the expiration of this patent, would have been free to use the claimed crystalline forms or processes, provided no other active patents were in force. If they aimed to market tamsulosin using a different crystalline form or a significantly different manufacturing process, they would need to demonstrate that their product was not covered by the expired claims or other active patents.
- Quality Control: Manufacturers must implement robust quality control measures, including analytical techniques like XRPD, to identify and quantify the crystalline form of the API being produced. This is essential for meeting regulatory requirements and ensuring product consistency. The patent highlights the importance of precise control over crystallization parameters to achieve the desired polymorphic form.
The expiration of this patent in 2015 removed a significant barrier for generic manufacturers looking to enter the market with tamsulosin hydrochloride products that utilize the specific crystalline forms described within.
Key Takeaways
- U.S. Patent 5,780,454 claims specific crystalline forms of tamsulosin hydrochloride, identified as Form I and Form II, along with various other numbered forms and associated production processes.
- These claimed crystalline forms are differentiated by their unique X-ray powder diffraction (XRPD) patterns, indicating distinct atomic arrangements.
- The patent's claims were designed to protect specific physical properties of tamsulosin hydrochloride that could influence solubility, stability, and manufacturing, thereby extending market exclusivity.
- The patent expired on July 14, 2015, removing a key intellectual property barrier for generic manufacturers.
- The expiration of this polymorph patent, in conjunction with the earlier expiration of the foundational tamsulosin compound patent (U.S. Patent 4,772,475), has facilitated generic market entry for tamsulosin hydrochloride.
- Manufacturing implications include the need to control polymorphic form during crystallization and to navigate existing and expired patent claims.
Frequently Asked Questions
-
When did U.S. Patent 5,780,454 expire?
U.S. Patent 5,780,454 expired on July 14, 2015.
-
What specific crystalline forms of tamsulosin hydrochloride are claimed in the patent?
The patent primarily claims "Form I" and "Form II," defined by specific X-ray powder diffraction (XRPD) patterns. It also references additional forms (Form III through Form XII) via accompanying figures.
-
Does the expiration of this patent allow immediate generic production of tamsulosin hydrochloride?
The expiration of U.S. Patent 5,780,454 permits the use of the claimed crystalline forms and processes for tamsulosin hydrochloride. However, generic manufacturers must also ensure they have freedom to operate concerning other potentially active patents, such as those covering specific formulations or manufacturing methods not claimed in Patent 5,780,454.
-
How are crystalline forms of a drug typically identified and differentiated in patent claims?
Crystalline forms are commonly identified and differentiated in patent claims using analytical techniques like X-ray Powder Diffraction (XRPD), which provides a unique diffraction pattern for each crystalline structure. Differential Scanning Calorimetry (DSC), Thermogravimetric Analysis (TGA), and Infrared Spectroscopy (IR) can also be used.
-
What is the primary therapeutic use of tamsulosin hydrochloride?
Tamsulosin hydrochloride is used to treat the signs and symptoms of benign prostatic hyperplasia (BPH), an enlarged prostate.
Citations
[1] Yamanouchi Pharmaceutical Co., Ltd. (1998). U.S. Patent 5,780,454: Crystalline form of tamsulosin hydrochloride. United States Patent and Trademark Office.
[2] Yamanouchi Pharmaceutical Co., Ltd. (1988). U.S. Patent 4,772,475: Process for preparing 5-[2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide and its salts. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
